Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2014

View Archived Issues

CytRx initiates phase IIb study of aldoxorubicin for SCLC

Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination trial

OncoMed and Bayer select small-molecule Wnt pathway inhibitor for preclinical development

Salvat reports topline phase III results for combination otic solution in AOMT

Erytech reports topline phase III data for Graspa

Ardelyx reports findings from phase IIb study of tenapanor for constipation-predominant IBS

Additional funding at Allakos to support second antibody candidate

Perrigo transfers preclinical research assets to Imago Pharmaceuticals

Esperion Therapeutics' phase IIb study of ETC-1002 for hypercholesterolemia meets primary endpoint

Phase I/II first-in-human results presented for lucitanib

XenoPort presents pharmacokinetic data for XP-23829

Bristol-Myers Squibb discloses new HCV NS3 NS4A protease inhibitors

Nanjing Sanhome Pharmaceutical patents novel anti-HCV nucleoside phosphoramidates

BTA-C585 shows excellent pharmacokinetic and safety profile in animal studies

AstraZeneca patent reports new inhibitors of activating mutant EGFRs

BI-415756, a novel potent CETP inhibitor for the treatment of cardiovascular diseases

New AMPK activators designed at Merck & Co.

Boehringer Ingelheim patent discloses novel DPP-I inhibitors

Higher serum CRTC3 associated with poorer metabolic profile in prepubertal children

NIH supports BRAIN Initiative with funding of USD 46 million

Linagliptin as potential treatment for uremic calcification

Novel PDE4 inhibitor designed by Chiesi for inhaled administration

Lilly to discontinue development of tabalumab

FDA grants fast track designation to NKTT-120 for the treatment of sickle cell disease

Islet Sciences and BHV Pharma enter merger agreement to form Avogenx

Bayer completes acquisition of Merck & Co.'s consumer healthcare business

Salix Pharmaceuticals and Cosmo Technologies terminate merger agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...